Rapport Therapeutics Lands $328M China Deal for Next-Gen Seizure Treatment RAP-219

Rapport Therapeutics partners with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China. $20M upfront + up to $308M milestones and tiered royalties for epilepsy & bipolar treatment.